Seres Therapeutics, Inc. (MCRB) 

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Show less

Over the last 12 months, insiders at Seres Therapeutics, Inc. have bought $0 and sold $92,717 worth of Seres Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Seres Therapeutics, Inc. have bought $9.18M and sold $666,149 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,912,748 shares for transaction amount of $9.18M was made by AFEYAN NOUBAR () on 2022‑07‑05.